Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Dipesh Navsaria MPH, MSLIS, MD
Dipesh Navsaria MPH, MSLIS, MD Advisory Board
Jonathan Temte MD, PhD
Jonathan Temte MD, PhD Advisory Board
Chill Yee MD
Chill C. Yee MD Advisory Board
See All Experts
featured
Published in Primary Care and
2 other channels

Journal Scan / Research · May 17, 2019

5α-Reductase Inhibitors Associated With Increased Time to Diagnosis and Mortality in Prostate Cancer

JAMA Internal Medicine

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Peter Lin MD, CCFP

JAMA Internal Medicine
Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer
JAMA Intern Med 2019 May 06;[EPub Ahead of Print], RR Sarkar, JK Parsons, AK Bryant, ST Ryan, AK Kader, RR McKay, AV D'Amico, PL Nguyen, BJ Hulley, JP Einck, AJ Mundt, CJ Kane, JD Murphy, BS Rose

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated